ScalaMed, which went through the TMC Accelerator in 2018, has been acquired. Photo via TMC

Healthcare services giant Cardinal Health has acquired Houston-based startup ScalaMed, whose platform transfers prescriptions directly to patients via a secure mobile app. The purchase price wasn’t disclosed.

ScalaMed now falls under the umbrella of a Cardinal-owned company called Outcomes. ScalaMed’s technology will be available throughout Cardinal’s nationwide pharmacy network.

“As healthcare continues to evolve toward patient preferences, the acquisition of ScalaMed allows us to center our connected ecosystem around the patient from the outset of their treatment journey — from the doctor’s office to the pharmacy to home,” Brent Stutz, senior vice president and general manager of Dublin, Ohio-based Outcomes, says in a news release. “Using ScalaMed’s technology, we can better support patients at every step along their treatment journey through unified communication and more informed insights that will help remove access and adherence barriers.”

Dr. Tal Rapke, founder and CEO of ScalaMed, says the process of digitizing prescriptions removes the patient from the equation, helping them bypass challenges such as forgetting medication while on vacation or lacking a convenient pharmacy nearby.

ScalaMed, founded in 2016 in Australia, raised $1.1 million in funding, according to Crunchbase. It was a member of the TMC Accelerator’s medtech program in 2018.

“With the scale and innovation Cardinal Health offers, we can revolutionize how prescriptions are filled and help solve the massive, costly challenge of medication nonadherence,” says Rapke, who’s a physician.

According to an article published in 2016 by the Journal of Managed Care & Specialty Pharmacy, medication nonadherence happens when a new medication is prescribed for a patient, but the patient does not obtain the medication or an appropriate alternative within an “acceptable” period after it was prescribed.

An article published in 2018 by The Permanente Journal reported that medication nonadherence happens with as many as 40 percent to 50 percent of patients who are prescribed drugs for chronic conditions like diabetes and high blood pressure. Each year, medication nonadherence costs the U.S. healthcare system $528 billion and contributes to about 275,000 avoidable patient deaths, according to a study published in 2018 in the Annals of Pharmacotherapy.

“Medication adherence … constitutes one of the ‘big hairy problems’ or ‘big hairy audacious goals’ of healthcare,” says an editorial published in 2020 by BMJ Journals.

gBETA has announced its second Houston cohort. Photo courtesy of gBETA

Early-stage startup accelerator names latest Houston cohort

ready cohort 2

An early-stage startup accelerator with a national presence has announced its latest cohorts across the country. Five Houston companies have been named to the local class.

The accelerator, gBETA, is a part of Madison, Wisconsin-based gener8tor's suite of accelerators, and announced its plan to launch in Houston in September 2019. The program's inaugural cohort premiered in May and conducted the first program this summer completely virtually.

This week, gBETA named 50 startups across 10 cohorts to its fall program. Here are the five startups selected from Houston:

  • DOSS: Launched in April, DOSS uses artificial intelligence and data aggregation in the homebuying process.
  • Camelia Alise: The company creates gender-neutral skincare products to treat pseudo-folliculitis condition and has developed a specific spa curriculum for aspiring spa owners and specialists.
  • CaseCTRL: A management platform for surgeons, CaseCTRL's software-as-a-service technology uses AI and logistics to lower operational costs and simplify surgical planning.
  • Melanoid Exchange: An online platform, Melanoid Exchange is giving small minority businesses the opportunity to grow their business through eCommerce.
  • ScalaMed: The company has developed a smart prescriptions platform that provides care teams real-time information on their patients' drug management, and patients with an empowering tool that helps them take control over the prescription process.

The no-cost, equity-free program will last seven weeks and kicked off on October 1. While the program will continue to be virtual, gBETA's operations are located in Amegy Bank's Downtown Launchpad along with Impact Hub Houston and MassChallenge Texas.

"Over the past year, Central Houston has focused on establishing Downtown as a vibrant innovative center of gravity for technology and entrepreneurship in the northern node of the Houston Innovation Corridor," says Robert Pieroni, director of economic development at Central Houston, a gBETA Houston sponsor, in the news release.

"The result has been recruiting nationally-acclaimed accelerator programs, such as gener8tor, to our city and creating Downtown Launchpad, an inclusive village that offers a framework of resources for these programs and the startups and entrepreneurs involved as they seamlessly navigate through the stages of startup production. We're thrilled that gener8tor is one of Downtown Launchpad's resident partners and look forward to the impact created by the startups in the fall cohort."

gBETA Houston's Virtual Pitch Night will be held on Wednesday, Nov. 18, at 5 pm. For more information and to RSVP, click here.

gBETA kicked off its 2020 fall accelerator virtually. Photo courtesy of gBETA

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston organizations launch collaborative center to boost cancer outcomes

new to HOU

Rice University's new Synthesis X Center officially launched last month to bring together experts in cancer care and chemistry.

The center was born out of what started about seven years ago as informal meetings between Rice chemist Han Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine. The level of collaboration between the two teams has grown significantly over the years, and monthly meetings now draw about 100 participants from across disciplines, fields and Houston-based organizations, according to a statement from Rice.

Researchers at the new SynthX Center will aim to turn fundamental research into clinical applications and make precision adjustments to drug properties and molecules. It will focus on improving cancer outcomes by looking at an array of factors, including prevention and detection, immunotherapies, the use of artificial intelligence to speed drug discovery and development, and several other topics.

"At Rice, we are strong on the fundamental side of research in organic chemistry, chemical biology, bioengineering and nanomaterials,” Xiao says in the statement. “Starting at the laboratory bench, we can synthesize therapeutic molecules and proteins with atom-level precision, offering immense potential for real-world applications at the bedside ... But the clinicians and fundamental researchers don’t have a lot of time to talk and to exchange ideas, so SynthX wants to serve as the bridge and help make these connections.”

SynthX plans to issue its first merit-based seed grants to teams with representatives from Baylor and Rice this month.

With this recognition from Rice, the teams from Xiao's lab and the TMC will also be able to expand and formalize their programs. They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

“I am confident that the SynthX Center will be a great resource for both students and faculty who seek to translate discoveries from fundamental chemical research into medical applications that improve people’s lives,” Thomas Killian, dean of the Wiess School of Natural Sciences, says in the release.

Rice announced that it had invested in four other research centers along with SynthX last month. The other centers include the Center for Coastal Futures and Adaptive Resilience, the Center for Environmental Studies, the Center for Latin American and Latinx Studies and the Rice Center for Nanoscale Imaging Sciences.

Earlier this year, Rice also announced its first-ever recipients of its One Small Step Grant program, funded by its Office of Innovation. The program will provide funding to faculty working on "promising projects with commercial potential," according to the website.

Houston physicist scores $15.5M grant for high-energy nuclear physics research

FUTURE OF PHYSICS

A team of Rice University physicists has been awarded a prestigious grant from the Department of Energy's Office of Nuclear Physics for their work in high-energy nuclear physics and research into a new state of matter.

The five-year $15.5 million grant will go towards Rice physics and astronomy professor Wei Li's discoveries focused on the Compact Muon Solenoid (CMS), a large, general-purpose particle physics detector built on the Large Hadron Collider (LHC) at CERN, a European organization for nuclear research in France and Switzerland. The work is "poised to revolutionize our understanding of fundamental physics," according to a statement from Rice.

Li's team will work to develop an ultra-fast silicon timing detector, known as the endcap timing layer (ETL), that will provide upgrades to the CMS detector. The ETl is expected to have a time resolution of 30 picoseconds per particle, which will allow for more precise time-of-flight particle identification.

The Rice team is collaborating with others from MIT, Oak Ridge National Lab, the University of Illinois Chicago and University of Kansas. Photo via Rice.edu

This will also help boost the performance of the High-Luminosity Large Hadron Collider (HL-LHC), which is scheduled to launch at CERN in 2029, allowing it to operate at about 10 times the luminosity than originally planned. The ETL also has applications for other colliders apart from the LHC, including the DOE’s electron-ion collider at the Brookhaven National Laboratory in Long Island, New York.

“The ETL will enable breakthrough science in the area of heavy ion collisions, allowing us to delve into the properties of a remarkable new state of matter called the quark-gluon plasma,” Li explained in a statement. “This, in turn, offers invaluable insights into the strong nuclear force that binds particles at the core of matter.”

The ETL is also expected to aid in other areas of physics, including the search for the Higgs particle and understanding the makeup of dark matter.

Li is joined on this work by co-principal investigator Frank Geurts and researchers Nicole Lewis and Mike Matveev from Rice. The team is collaborating with others from MIT, Oak Ridge National Lab, the University of Illinois Chicago and University of Kansas.

Last year, fellow Rice physicist Qimiao Si, a theoretical quantum physicist, earned the prestigious Vannevar Bush Faculty Fellowship grant. The five-year fellowship, with up to $3 million in funding, will go towards his work to establish an unconventional approach to create and control topological states of matter, which plays an important role in materials research and quantum computing.

Meanwhile, the DOE recently tapped three Houston universities to compete in its annual startup competition focused on "high-potential energy technologies,” including one team from Rice.

------

This article originally ran on EnergyCapital.